Trial results presented at a recent medical conference demonstrated that the use of shorter duration radiation is safe and effective in prostate cancer, as well as a type of rare cancer, according to an expert.
Investigators of the phase 3 ALINA trial report no unexpected safety findings with alectinib in ALK-positive non–small cell lung cancer.
Results from the phase 3 RATIONALE 302 trial led to the approval of tislelizumab for patients with unresectable or metastatic esophageal squamous cell carcinoma.
A series of phase 3 findings support the European approval of tislelizumab as a first-line and second-line treatment for non–small cell lung cancer.
ME-344 and bevacizumab can now have an additional 20 patients enrolled on the phase 1b trial for relapsed metastatic colorectal cancer.
The FDA approval of the single-agent, oral pan-RAF inhibitor tovorafenib is based on efficacy results from the phase 2 FIREFLY-1 trial.
DCISionRT is a risk-assessment test for patients designed to predict RT benefit and develop their recurrence risk after surgery alone or with radiation.
Data from 2 NETTER trials support lutetium Lu 177 dotatate’s approval in somatostatin receptor-positive gastroenteropancreatic neuroendocrine tumors.
Nogapendekin alfa-inbakicept is now approved for the treatment of patients with BCG-unresponsive non-muscle invasive bladder carcinoma.
The latest KEYNOTE-756 data highlight the surgical outcomes of patients with high-risk early-stage estrogen receptor–positive breast cancer.
In clinically node-positive breast cancer, clipping of lymph nodes may induce higher rates of sentinel lymph node surgery after neoadjuvant chemotherapy.
